JP2018508572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508572A5 JP2018508572A5 JP2017560890A JP2017560890A JP2018508572A5 JP 2018508572 A5 JP2018508572 A5 JP 2018508572A5 JP 2017560890 A JP2017560890 A JP 2017560890A JP 2017560890 A JP2017560890 A JP 2017560890A JP 2018508572 A5 JP2018508572 A5 JP 2018508572A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- immune checkpoint
- inhibitor
- cancer
- checkpoint inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022175377A JP7564172B2 (ja) | 2015-02-12 | 2022-11-01 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2024167302A JP2024174070A (ja) | 2015-02-12 | 2024-09-26 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115468P | 2015-02-12 | 2015-02-12 | |
| US62/115,468 | 2015-02-12 | ||
| US201562255259P | 2015-11-13 | 2015-11-13 | |
| US62/255,259 | 2015-11-13 | ||
| PCT/US2016/017602 WO2016130839A1 (en) | 2015-02-12 | 2016-02-11 | Use of plinabulin in combination with immune checkpoint inhibitors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001505A Division JP7157181B2 (ja) | 2015-02-12 | 2021-01-07 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2022175377A Division JP7564172B2 (ja) | 2015-02-12 | 2022-11-01 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508572A JP2018508572A (ja) | 2018-03-29 |
| JP2018508572A5 true JP2018508572A5 (enExample) | 2019-03-22 |
| JP7243021B2 JP7243021B2 (ja) | 2023-03-22 |
Family
ID=56615698
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560890A Active JP7243021B2 (ja) | 2015-02-12 | 2016-02-11 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2021001505A Active JP7157181B2 (ja) | 2015-02-12 | 2021-01-07 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2022175377A Active JP7564172B2 (ja) | 2015-02-12 | 2022-11-01 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2024167302A Pending JP2024174070A (ja) | 2015-02-12 | 2024-09-26 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001505A Active JP7157181B2 (ja) | 2015-02-12 | 2021-01-07 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2022175377A Active JP7564172B2 (ja) | 2015-02-12 | 2022-11-01 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
| JP2024167302A Pending JP2024174070A (ja) | 2015-02-12 | 2024-09-26 | 免疫チェックポイント阻害薬と併用するプリナブリンの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180028531A1 (enExample) |
| EP (1) | EP3256130A4 (enExample) |
| JP (4) | JP7243021B2 (enExample) |
| KR (2) | KR20240110996A (enExample) |
| CN (2) | CN107427510A (enExample) |
| AU (3) | AU2016219204B2 (enExample) |
| CA (1) | CA2975729A1 (enExample) |
| CL (1) | CL2017002050A1 (enExample) |
| HK (1) | HK1247816A1 (enExample) |
| IL (2) | IL286282B2 (enExample) |
| MX (2) | MX394865B (enExample) |
| MY (1) | MY193968A (enExample) |
| NZ (1) | NZ734256A (enExample) |
| RU (1) | RU2723021C2 (enExample) |
| SG (1) | SG11201706281YA (enExample) |
| WO (1) | WO2016130839A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120923A1 (es) | 2009-03-30 | 2012-08-27 | Eisai Randd Man Co Ltd | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| HK1249052A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| WO2016144636A1 (en) | 2015-03-06 | 2016-09-15 | Beyondspring Pharmaceuticals, Inc. | Method of treating a brain tumor |
| NZ738406A (en) * | 2015-06-11 | 2023-04-28 | Bionomics Ltd | Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof |
| EP3334726B1 (en) | 2015-07-13 | 2022-03-16 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN109475524A (zh) | 2016-06-06 | 2019-03-15 | 万春药业公司 | 用于减少中性粒细胞减少症的组合物和方法 |
| EP3505183B1 (en) * | 2016-08-26 | 2022-03-30 | Tetsuji Okuno | Microvascular blood flow decreasing agent and use thereof |
| SG11201902974PA (en) * | 2016-10-14 | 2019-05-30 | Merck Sharp & Dohme | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals, Inc. | composições de plinabulina e seu uso |
| JP6956254B2 (ja) * | 2017-07-26 | 2021-11-02 | チョン クン ダン ファーマシューティカル コーポレーション | 血管遮断剤および免疫チェックポイント阻害剤を含む癌の予防または治療用の組成物 |
| JP7343483B2 (ja) | 2017-09-08 | 2023-09-12 | ユニバーシティー ヘルス ネットワーク | Ｐｏｌｏ様キナーゼ４の阻害のための併用療法 |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| WO2019147615A1 (en) * | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| US20210161888A1 (en) * | 2018-06-01 | 2021-06-03 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| KR20210047309A (ko) * | 2018-08-16 | 2021-04-29 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 면역 반응을 자극하기 위한 방법 및 조성물 |
| JP7501922B2 (ja) * | 2018-11-01 | 2024-06-18 | ノース カロライナ ステート ユニバーシティ | 脂肪細胞を介した抗癌治療薬の送達 |
| CN110265095A (zh) * | 2019-05-22 | 2019-09-20 | 首都医科大学附属北京佑安医院 | 用于hcc复发及rfs的预测模型和诺模图的构建方法及应用 |
| ES3075649T3 (en) | 2019-07-26 | 2026-08-06 | Eisai R&D Man Co Ltd | Pharmaceutical composition for treating tumor |
| CN112778155B (zh) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
| KR20230006568A (ko) * | 2020-05-04 | 2023-01-10 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법 |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| CN117615761A (zh) * | 2021-04-09 | 2024-02-27 | 大连万春布林医药有限公司 | 用于治疗肿瘤的治疗组合物和方法 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| JP2026509292A (ja) * | 2023-03-10 | 2026-03-17 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍学的併用療法及びその使用方法 |
| WO2025006507A1 (en) * | 2023-06-27 | 2025-01-02 | Beyondspring Pharmaceuticals, Inc. | Oncology combination therapy and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003302721B2 (en) * | 2002-08-02 | 2009-10-08 | Beyondspring Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| BRPI0506655A (pt) * | 2004-02-04 | 2007-05-08 | Nereus Pharmaceuticals Inc | dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US8569262B2 (en) * | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US8449886B2 (en) * | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| JP2012505920A (ja) * | 2008-10-17 | 2012-03-08 | エグゼリクシス， インコーポレイテッド | スフィンゴシン１リン酸塩受容体拮抗薬 |
| EA201200486A1 (ru) * | 2009-09-15 | 2012-08-30 | Серулин Фарма Инк. | Лечение онкологических заболеваний |
| US20130064831A1 (en) * | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| WO2013090552A1 (en) * | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| EA201590451A1 (ru) * | 2012-08-30 | 2016-05-31 | Эмджен Инк. | Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки |
| CA2889182A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| SG11201505896YA (en) * | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP2958571B1 (en) * | 2013-02-21 | 2024-04-10 | Michele Maio | Dna hypomethylating agents for cancer therapy |
| US10260038B2 (en) * | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| AU2014276440A1 (en) * | 2013-06-03 | 2015-11-05 | Novartis Ag | Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor |
| EP3076972B1 (en) * | 2013-10-11 | 2021-10-06 | BeyondSpring, Inc. | Cancer treatment with combination of plinabulin and taxane |
| US10912748B2 (en) * | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
-
2016
- 2016-02-11 MX MX2017010338A patent/MX394865B/es unknown
- 2016-02-11 SG SG11201706281YA patent/SG11201706281YA/en unknown
- 2016-02-11 IL IL286282A patent/IL286282B2/en unknown
- 2016-02-11 MY MYPI2017702826A patent/MY193968A/en unknown
- 2016-02-11 JP JP2017560890A patent/JP7243021B2/ja active Active
- 2016-02-11 HK HK18107194.9A patent/HK1247816A1/zh unknown
- 2016-02-11 AU AU2016219204A patent/AU2016219204B2/en active Active
- 2016-02-11 KR KR1020247022015A patent/KR20240110996A/ko active Pending
- 2016-02-11 NZ NZ734256A patent/NZ734256A/en unknown
- 2016-02-11 CN CN201680015268.XA patent/CN107427510A/zh active Pending
- 2016-02-11 US US15/550,350 patent/US20180028531A1/en not_active Abandoned
- 2016-02-11 WO PCT/US2016/017602 patent/WO2016130839A1/en not_active Ceased
- 2016-02-11 CA CA2975729A patent/CA2975729A1/en active Pending
- 2016-02-11 CN CN202311274843.6A patent/CN117100753A/zh active Pending
- 2016-02-11 EP EP16749903.7A patent/EP3256130A4/en active Pending
- 2016-02-11 RU RU2017127966A patent/RU2723021C2/ru active
- 2016-02-11 KR KR1020177025140A patent/KR20170117113A/ko not_active Ceased
-
2017
- 2017-08-01 IL IL253784A patent/IL253784B/en unknown
- 2017-08-10 CL CL2017002050A patent/CL2017002050A1/es unknown
- 2017-08-10 MX MX2022007472A patent/MX2022007472A/es unknown
-
2021
- 2021-01-07 JP JP2021001505A patent/JP7157181B2/ja active Active
- 2021-04-21 AU AU2021202416A patent/AU2021202416B2/en active Active
-
2022
- 2022-11-01 JP JP2022175377A patent/JP7564172B2/ja active Active
-
2024
- 2024-02-02 AU AU2024200672A patent/AU2024200672B2/en active Active
- 2024-09-26 JP JP2024167302A patent/JP2024174070A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017127966A (ru) | Применение плинабулина в комбинации с ингибиторами контрольной точки иммунного ответа | |
| JP2019511565A5 (enExample) | ||
| Constantinidou et al. | Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy | |
| IL292658A (en) | Immune modulation with tlr9 agonists for cancer treatment | |
| JP2022088662A5 (enExample) | ||
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| RU2020124007A (ru) | Комбинированный препарат, включающий агонист tlr7 | |
| UY37758A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
| HRP20202042T1 (hr) | Modulacija tumorske imunosti | |
| FI3827838T3 (fi) | Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa | |
| RU2020127099A (ru) | Способ улучшения функции иммунных клеток и оценки мультифункциональности иммунных клеток | |
| JP2017095457A5 (enExample) | ||
| JP2020517913A5 (enExample) | ||
| RU2017107681A (ru) | Производные хиназолина | |
| Urba et al. | Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma | |
| Huang et al. | Development and characterization of a bispecific antibody (GB265) against PD-L1 and TIGIT | |
| Andrews et al. | Abstract A060: Inhibition of Aurora B kinase activity triggers senescence that can be bypassed by blocking p53 and RB function, promoting replication stress | |
| Lui et al. | Abstract A232: Novel thiosemicarbazones with potent antitumor and antimetastatic activity inhibit the signal transducer and activator of transcription (STAT) pathway. | |
| Abbineni et al. | Abstract A046: Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers | |
| Yu et al. | In vivo combination of miransertib (ARQ 092) with anti-PD-1 antibody, trametinib, lapatinib, trastuzumab and paclitaxel | |
| Schooten | Multispecific antibodies targeting CD38 and PD-L1 show potent tumor cytotoxicity | |
| Kato et al. | Abstract C167: Establishment of a cancer-specific anti-podoplanin antibody not reacting with lymphatic endothelial cells. | |
| Finn | Abstract MS1-2: Targeting CDK 4/6 in breast cancer | |
| Sainz et al. | Pancreatic cancer stem cell metastasis and mitochondrial respiration is dependent on the the ISG15-mediated ubiquitin-like modification process known as ISGylation | |
| Weng et al. | A TCL1-specific T-cell receptor redirects T cells against B-cell lymphomas and non-hematological tumors |